|1.||Page, Clive P: 2 articles (01/2014 - 08/2010)|
|2.||Stafford, Randall S: 2 articles (12/2011 - 04/2003)|
|3.||Piosik, Jacek: 2 articles (02/2002 - 02/2002)|
|4.||Zdunek, Malgorzata: 2 articles (02/2002 - 02/2002)|
|5.||Kapuscinski, Jan: 2 articles (02/2002 - 02/2002)|
|6.||Chen, Lijuan: 1 article (05/2015)|
|7.||Pei, Heying: 1 article (05/2015)|
|8.||Ran, Yan: 1 article (05/2015)|
|9.||Ma, Liang: 1 article (05/2015)|
|10.||Xie, Caifeng: 1 article (05/2015)|
|1.||Asthma (Bronchial Asthma)
12/01/1990 - "Xanthines are effective in the treatment of asthma, but the mechanism of action remains unclear. "
08/22/1986 - "The results obtained with Ca2+ antagonists, which are poorly effective in asthma, compared to the established antiasthma drugs, xanthines and beta 2-receptor agonists, may indicate that depolarization-induced mechanisms contribute little to bronchoconstriction in asthma."
05/01/1991 - "Hence mechanisms other than bronchodilatation and "functional antagonism" should be considered to explain the protection against constrictor stimuli in asthma seen with beta 2 agonists and xanthines."
01/01/2006 - "Our data suggest that xanthines are only suitable as first-line preventative asthma therapy in children when ICS are not available. "
01/01/2006 - "Xanthines as first-line preventer alleviate symptoms and reduce requirement for rescue medication in children with mild to moderate asthma. "
03/01/2000 - "The xanthines have been shown to be effective in the treatment of apnea of prematurity. "
11/01/1997 - "One hundred seventy-five infants were excluded because they never experienced apnea, or data about the last apnea was missing, or they were on xanthines during the period encompassing the last 3 apnea days, or they weighed <1500 g or were <34 weeks' postmenstrual age at the time of the last apnea. "
06/01/1993 - "Xanthines are used to treat apnea, but their mechanism of action is not clearly understood. "
05/01/1987 - "[Xanthines in apnea of premature infants. "
02/01/1976 - "Letter: The use of xanthines in treating apnea of prematurity."
|3.||Lung Diseases (Lung Disease)
02/01/2012 - "Xanthines such as theophylline have been used in the treatment of lung diseases since the early 1900's, but have a major drawback of a very narrow therapeutic window and many drug/drug interactions. "
08/01/2010 - "Xanthines such as theophylline have been used in the treatment of lung diseases since the early 1900's, but have a major drawback of a very narrow therapeutic window and many drug/drug interactions. "
08/01/2010 - "Doxofylline is a xanthine molecule that appears to be both bronchodilator and anti-inflammatory with an improved therapeutic window over conventional xanthines such as theophylline and the evidence supporting the effects of doxofylline in the treatment of lung diseases is discussed."
|5.||Autoimmune Diseases (Autoimmune Disease)
05/01/2000 - "This review mainly covers PDE 4 inhibitors structurally related to xanthines and Nitraquazone, which appear to be very attractive models for the synthesis of novel PDE 4 inhibitors potentially useful for the treatment of asthma, chronic pulmonary obstructive disease and some autoimmune diseases. "
|3.||Phosphodiesterase 4 Inhibitors
|4.||TVX 2706 (nitraquazone)
|6.||Caffeine (No Doz)
|8.||Purinergic P1 Receptors (Adenosine Receptor)
|10.||Adenosine A1 Receptor
|3.||Renal Dialysis (Hemodialysis)